Tag: Anavex Life Sciences (AVXL)

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Anavex Life Sciences Promising News From Anavex Life Sciences  (AVXL) we learned that The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of application for a Union Marketing Authorization in the EU under the European Medicines Agency’s centralized procedure . . . This content is for paid subscribers. Please click here …

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

Anavex Life Sciences Granted US Patent Anavex Life Sciences (AVXL) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.